dotMD.com
Bacterial, Viral & Fungal Infections • ICD-10-CM B35.3

Blisters

Also known as: Bulla, Vesicle

Audited by the DotMD AI Specialist Council • FDA DailyMed SPL: 2026-11-02 • ICD-10-CM B35.3 • 5 Linked .gov / PubMed Citations • Governance: Dr. Priya Nair, MD, FAAD (NPI #1295730425)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary

Blisters Key Takeaways

Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about Blisters

3 of 3 Free Questions Remaining

What Is Blisters?

What are blisters? Blisters are fluid-filled sacs on the outer layer of your skin. They form because of rubbing, heat, or diseases of the skin. They are most common on your hands and feet. Other names for blisters are vesicles (usually for smaller blisters) and bulla (for larger blisters). What causes blisters? Blisters often happen when there is friction - rubbing or pressure - on one spot. For example, if your shoes don't fit quite right and they keep rubbing part of your foot. Or if you don't wear gloves when you rake leaves and the handle keeps rubbing against your hand.

Pathophysiology, Underlying Causes & Clinical Presentation

Tissue-level etiology in Blisters (B35.3) features or fungal) epithelial in Blisters (B35.3: invasion). Cross-referenced with NIH MeSH (Blister), therapeutic stabilization in infections & antivirals is verified against Complete Blood Count in Blisters (B35.3: (WBC & Differential)).

Common Symptoms & Clinical Signs

  • • Allergic reactions
  • • Poison ivy, oak, and sumac
  • • Presentation of Blisters (B35.3): painful vesicular rash in Blisters (B35.3: in a dermatomal)
  • • Secondary Blisters clinical sign: regional lymph node in Blisters (B35.3: tenderness or acute)

Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗

Blisters Diagnostic Classification & Lab Markers

Metric Verified Benchmark Source
ICD-10-CM Diagnostic Code B35.3 WHO / CMS ICD-10-CM Clinical Classification
Clinical Specialty Hub Bacterial, Viral & Fungal Infections NIH MedlinePlus Health Topics
Diagnostic / Lab Marker: Targeted PCR / in Blisters (B35.3: Culture & Sensitivity) Pathogen clearance / negative test (B35.3) Clinical Reference Target Range
Diagnostic / Lab Marker: Complete Blood Count in Blisters (B35.3: (WBC & Differential)) WBC 4.0 – 10.0 x10^3/uL (B35.3) Clinical Reference Target Range
Diagnostic / Lab Marker: C-Reactive Protein / in Blisters (B35.3: Procalcitonin) Resolution to baseline (B35.3) Clinical Reference Target Range
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance

FDA-Monographed Medications & Public Cash Price Reference for Blisters

Check Drug Interactions →

Treatment selection for Blisters depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.

Dr. Lin (AI PubMed Clinical Trial Lead)

Peer-Reviewed Human Clinical Trials & Meta-Analyses (Blisters)

Browse All PubMed Translations →
Study & Plain-English Finding Sample (N) Rigor Primary Source
Kids With the Flu: How an Herbal Remedy Stacked Up Against Tamiflu in a 520-Child Trial

LHQW was non-inferior to oseltamivir in clinical recovery time and resulted in faster defervescence and greater improvement in cough and sore throat, with comparable safety.

Pharmaceutical biology • 2026-12-15 • Randomized Controlled Trial
N = 520 93/100 PMID 42947434 ↗
Can This Approach Help? Inside the Latest Research on Immunogenicity and safety of the first indigenously developed Indian tetravalent

Both the vaccines were tolerated well by all the study participants, and an addition of the fourth strain in TetIV did not compromise the safety as compared to that of TriIV.

Human vaccines & immunotherapeutics • 2021-03-04 • Phase III Randomized Trial
Multi-cohort 82/100 PMID 32845782 ↗
Zero-PHI Patient Support & Cohort Discussions

Blisters Patient Community & “People Like Me” Threads

“People Like Me” Cohort Filter (Zero-PHI)

Filter Blisters community threads and patient logs by age, biological sex, dosage, and treatment duration.

No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Blisters.

Related Conditions in Bacterial, Viral & Fungal Infections